Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Ischemic Heart Disease

Free Subscription 22.12.2025 2 Am J Cardiol 8 Ann Intern Med 2 Arterioscler Thromb Vasc Biol 2 Atherosclerosis 3 Can J Cardiol 2 Catheter Cardiovasc Interv 2 Circ Cardiovasc Imaging 1 Circ Heart Fail 1 Circ Res 1 Circulation 1 Clin Cardiol 1 Clin Chem 2 Hypertension 7 Int J Cardiol 1 J Am Coll Cardiol 2 J Cardiovasc Pharmacol 1 N Engl J Med 3 PLoS One 1 Thromb Haemost

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Cardiol

1. BAUDO M, Leone PP, Sicouri S, Magouliotis D, et al
   Transcatheter or Surgical Strategy for Aortic Stenosis and Coronary Artery Disease: A Kaplan-Meier-Derived Meta-Analysis.
   Am J Cardiol. 2025 Dec 15:S0002-9149(25)00721.
   PubMed         Abstract available
   
   
2. NAVARRO SP, Hammonds K, Mixon T, Potluri S, et al
   Revascularization in Patients Over 75 with Acute Coronary Syndrome.
   Am J Cardiol. 2025 Dec 12:S0002-9149(25)00717.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

3. LEIVA O, Elgendy IY
   In adults with MI and LVEF >40% after invasive care, beta-blocker therapy did not reduce a composite adverse outcome at a median 3.7 y.
   Ann Intern Med. 2025;178:JC134.
   PubMed         Abstract available
   
   
4. LEIVA O, Elgendy IY
   In adults with MI and LVEF >/=40%, beta-blocker therapy reduced a composite adverse outcome at a median 3.5 y.
   Ann Intern Med. 2025;178:JC135.
   PubMed         Abstract available
   
   
5. BATES ER
   P2Y12 inhibitor monotherapy soon after PCI for ACS was not noninferior to DAPT for a composite of death or ischemic events.
   Ann Intern Med. 2025;178:JC137.
   PubMed         Abstract available
   
   
6. BATES ER
   After successful PCI for AMI and 1 mo of DAPT, P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse outcomes.
   Ann Intern Med. 2025;178:JC136.
   PubMed         Abstract available
   
   
7. LIM LS
   In healthy older adults, low-dose aspirin for a median 4.7 y did not reduce MACE but increased major hemorrhage at a median 8.3 y.
   Ann Intern Med. 2025;178:JC139.
   PubMed         Abstract available
   
   
8. STEEN JP, Klatt KC, Chang Y, Guyatt GH, et al
   Effect of Interventions Aimed at Reducing or Modifying Saturated Fat Intake on Cholesterol, Mortality, and Major Cardiovascular Events : A Risk Stratified Systematic Review of Randomized Trials.
   Ann Intern Med. 2025 Dec 16. doi: 10.7326/ANNALS-25-02229.
   PubMed         Abstract available
   
   
9. ESTRUCH R, Lamuela-Raventos RM
   Saturated Fats and Cardiovascular Disease: From Avoidance to a Nuanced Recommendation.
   Ann Intern Med. 2025 Dec 16. doi: 10.7326/ANNALS-25-04971.
   PubMed        
   
   
10. 
    Annals Video Summary - Effect of Interventions Aimed at Reducing or Modifying Saturated Fat Intake on Cholesterol, Mortality, and Major Cardiovascular Events.
    Ann Intern Med. 2025 Dec 16:e2504737VS. doi: 10.7326/ANNALS-25-04737.
    PubMed        
    
    

    
    Arterioscler Thromb Vasc Biol

11. WEINTRAUB NL, Guha A, Taskar V, Elam RE, et al
    Cardiovascular Manifestations and Immunobiology of Sarcoidosis.
    Arterioscler Thromb Vasc Biol. 2025 Dec 18. doi: 10.1161/ATVBAHA.125.323111.
    PubMed         Abstract available
    
    
12. MUIR KC, Stone C, Reddy R, Kanuparthy M, et al
    Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling.
    Arterioscler Thromb Vasc Biol. 2025 Dec 18. doi: 10.1161/ATVBAHA.125.323916.
    PubMed         Abstract available
    
    

    
    Atherosclerosis

13. JOHANSEN MO, Vedel-Krogh S, Nielsen SF, Afzal S, et al
    Remnant cholesterol and particle number of VLDL subfractions in coronary artery disease: Pros and cons.
    Atherosclerosis. 2026;412:120605.
    PubMed         Abstract available
    
    
14. UEKI Y, Kakizaki R, Otsuka T, Itagaki T, et al
    Effect of alirocumab on coronary plaque stratified by atherothrombotic risk.
    Atherosclerosis. 2026;412:120588.
    PubMed         Abstract available
    
    

    
    Can J Cardiol

15. LIU M, Du Y, Cui C, Li C, et al
    Distal Radial Artery Access With 6F and 7F Thin-Walled Sheaths for Coronary Intervention: A Multicentre, Randomized, DRAWS Trial Protocol.
    Can J Cardiol. 2025;41:2420-2428.
    PubMed         Abstract available
    
    
16. LIU Y, Zhou Y, Lin X, Zeng L, et al
    Postprocedural Parenteral Anticoagulation in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
    Can J Cardiol. 2025;41:2509-2519.
    PubMed         Abstract available
    
    
17. BELLEY-COTE EP, Whitlock RP, Lamy A, Alhussein MM, et al
    Association Between Electrocardiographic Changes and Myocardial Injury or Death After Cardiac Surgery.
    Can J Cardiol. 2025;41:2601-2610.
    PubMed         Abstract available
    
    

    
    Catheter Cardiovasc Interv

18. ZHANG H, Zhang X, Li T, Zhou Y, et al
    Development of a Prediction Model for Major Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction Following Percutaneous Coronary Intervention.
    Catheter Cardiovasc Interv. 2025 Dec 15. doi: 10.1002/ccd.70422.
    PubMed         Abstract available
    
    
19. LI J, Liu LF, Lamu G, Jin Y, et al
    Elevated Hemoglobin Levels and Risk of ST-Segment Elevation Myocardial Infarction in High-Altitude Acute Coronary Syndrome: A Retrospective Analysis.
    Catheter Cardiovasc Interv. 2025 Dec 15. doi: 10.1002/ccd.70426.
    PubMed         Abstract available
    
    

    
    Circ Cardiovasc Imaging

20. ABOHASHEM S, Qamar I, Grewal SS, Civieri G, et al
    Depression and Anxiety Associate With Adverse Cardiovascular Events via Neural, Autonomic, and Inflammatory Pathways.
    Circ Cardiovasc Imaging. 2025 Dec 17:e017706.
    PubMed         Abstract available
    
    
21. KADOYA Y, Da Silva E, AlTakroni L, Hejji N, et al
    Prognostic Utility of Quantitative Perfusion PET in Patients With Prior CABG: Incremental Value of Myocardial Flow Reserve and Coronary Vascular Resistance.
    Circ Cardiovasc Imaging. 2025 Oct 27:e018204.
    PubMed         Abstract available
    
    

    
    Circ Heart Fail

22. JUNG C, Lang A, Duse DA, Bruno RR, et al
    Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock.
    Circ Heart Fail. 2025;18:e012890.
    PubMed         Abstract available
    
    

    
    Circ Res

23. SINGHAL R, Ferrari I, Brainard RE, Brittian KR, et al
    Temporal Dynamics in Murine Cardiac Transcriptome Following Myocardial Infarction.
    Circ Res. 2025 Dec 18. doi: 10.1161/CIRCRESAHA.125.327367.
    PubMed        
    
    

    
    Circulation

24. TRAN AH, Zaidi AH, Bolger AF, Del Brutto OH, et al
    Periodontal Disease and Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2025 Dec 16. doi: 10.1161/CIR.0000000000001390.
    PubMed         Abstract available
    
    

    
    Clin Cardiol

25. RASHID H
    Letter to the Editor: Long-Term Effectiveness of a Stent-Less Strategy With Drug-Coated Balloon in Coronary Artery Disease: 3-Year Follow-Up.
    Clin Cardiol. 2025;48:e70236.
    PubMed        
    
    

    
    Clin Chem

26. DASCHNER C, Kleber ME, Berg AH, Husain-Syed F, et al
    Association of Serum Uromodulin and Carbamylated Albumin with All-Cause and Cardiovascular Mortality in Patients with No or Mild Chronic Kidney Disease.
    Clin Chem. 2025 Dec 16:hvaf166. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Hypertension

27. NARITA K, Hoshide S, Tomitani N, Fujiwara T, et al
    Predicted Cardiovascular Risk by the PREVENT Equations and Prevalence of Masked Hypertension Assessed by Home Blood Pressure Monitoring.
    Hypertension. 2026;83:238-241.
    PubMed        
    
    
28. CHEN H, Xu J, Huang Q, Zhao J, et al
    Kif23 Promotes Myocardial Fibrosis by Suppressing Ces1d-Dependent Lipid Metabolism.
    Hypertension. 2026;83:116-129.
    PubMed         Abstract available
    
    

    
    Int J Cardiol

29. DE VITA A, Marino AG, Cambise N, Lamendola P, et al
    Coronary microvascular dysfunction in patients with acute coronary syndrome and non-obstructive coronary artery disease: a 10-year clinical follow-up study.
    Int J Cardiol. 2026;445:134031.
    PubMed         Abstract available
    
    
30. BRUCATO F, Tognola C, Moreo A, Bellomare M, et al
    Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study.
    Int J Cardiol. 2026;445:134046.
    PubMed         Abstract available
    
    
31. DAYAWANSA NH, Vogrin S, Zheng WC, Lefkovits J, et al
    Safety and performance of complex percutaneous coronary intervention in centres with and without on-site cardiac surgery: A multi-centre Australian study.
    Int J Cardiol. 2025 Nov 17:134032. doi: 10.1016/j.ijcard.2025.134032.
    PubMed         Abstract available
    
    
32. HADA M, Hoshino M, Watanabe T, Usui E, et al
    Determinants and prognostic significance of microvascular resistance reserve stratified by functional severity of epicardial stenosis.
    Int J Cardiol. 2026;445:134027.
    PubMed         Abstract available
    
    
33. JAMAL J, Yang K, Ediriweera T, O'Loughlin A, et al
    Early and late outcomes of patients presenting with STEMI in the absence of standard modifiable risk factors: a reperfusion strategy aggregated analysis.
    Int J Cardiol. 2026;445:134008.
    PubMed         Abstract available
    
    
34. HOTCHI Y, Tanaka R, Kojima Y, Shiozaki M, et al
    Validation of the 0/1-hour cardiac myosin-binding protein C algorithm and establishment of sex-specific reference limits in a Japanese population.
    Int J Cardiol. 2026;445:134082.
    PubMed         Abstract available
    
    
35. SLEGERS DPJ, Bova R, Heuts SFM, Betti M, et al
    Diffuse coronary artery disease leads to deferral of both surgical and percutaneous coronary artery revascularisation.
    Int J Cardiol. 2026;445:134049.
    PubMed         Abstract available
    
    

    
    J Am Coll Cardiol

36. KRAMER CM
    The Cardiovascular Imager of the Future.
    J Am Coll Cardiol. 2025 Dec 17:S0735-1097(25)10276.
    PubMed        
    
    

    
    J Cardiovasc Pharmacol

37. TEPERIKIDIS L, Boulmpou A, Chownk M, Jagdale R, et al
    Colchicine for Major Adverse Cardiovascular Events: An Updated ChatGPT-Assisted Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2025 Nov 25. doi: 10.1097/FJC.0000000000001780.
    PubMed         Abstract available
    
    
38. ZHANG J, Chen X, Wan C
    Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
    J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722.
    PubMed         Abstract available
    
    

    
    N Engl J Med

39. NICHOLLS SJ, Pavo I, Bhatt DL, Buse JB, et al
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    N Engl J Med. 2025;393:2409-2420.
    PubMed         Abstract available
    
    

    
    PLoS One

40. AKDENIZ E, Hunuk B, Yildiz C, Abdullahoglu SD, et al
    ACEF score as a predictor of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction: A retrospective cohort study.
    PLoS One. 2025;20:e0339483.
    PubMed         Abstract available
    
    
41. WU J, Zhai J, Zhu X, Hao Q, et al
    Epidemiological characteristics of ischemic heart disease: A comparative study between China and the world from 1990 to 2021 and prediction to 2036.
    PLoS One. 2025;20:e0336963.
    PubMed         Abstract available
    
    
42. LUBBERING N, Krogmann A, Jansen F, Latz E, et al
    Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography.
    PLoS One. 2025;20:e0338635.
    PubMed         Abstract available
    
    

    
    Thromb Haemost

43. CAMERA M, Brambilla M, Cosentino N, Becchetti A, et al
    Tissue factor, a membrane-associated marker of platelet activation, predicts 5-year cardiovascular mortality in coronary artery disease patients.
    Thromb Haemost. 2025 Dec 15. doi: 10.1055/a-2771-2148.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.